The Covid-19 pandemic is shaking up well-established business models and dispelling long-held assumptions, holding out an opportunity to reshape and democratise healthcare around the planet.
The future will call for a new approach to prevention, screening, diagnosis, therapy, monitoring and management of diseases. We are likely to see convergence of translational research in biomedicine with disciplines such as public health, epidemiology, infectious disease modelling and data science. The multidisciplinary approach will demand a reimagining of biomedical innovation.
The availability of genetic information, together with other phenotypic as well as medical information, is helping identify new drug targets by linking particular genes and their products to individual diseases. In addition to genomic data, other data have also moved into the spotlight. Proteomics and metabolomics, as well as epigenetics and an integrated view of all of these disciplines, are gaining traction. Also, the impact of lifestyle choices is starting to be factored in.
On the other end of the spectrum, electronic health records and other patient-related information in registries and hospital administration databases are helping establish real-world evidence for effectiveness of a particular medicine.
Researchers today are relying on multiplexed data sets to make drug discovery and development more innovative, cheaper and faster.
Data Science For Affordable Innovation
Drug discovery is capital intensive, research-intensive and intellectual property-intensive with inherently long time lines.
This story is from the August 23, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the August 23, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Look Before You Leap
In 2025, Investors Will Need To Factor In Volatility Across Asset Classes
"Focus on the challenge of each customer"
SHASHANK KUMAR MD & CO-FOUNDER I RAZORPAY Razorpay is India's first full-stack financial solutions company
PEDAL ON THE FUTURE
THE MG WINDSOR EV, WITH ITS FUTURISTIC AND MINIMALIST DESIGN, COMBINES THE BEST OF BOTH WORLDS-COMFORT AND TECHNOLOGY
BREATHE EASY
Whether you're battling allergies, looking to remove pollutants, or simply want to breathe easier, the right air purifier can make a difference
The Taste of India in a Glass
FROM ROYAL LIQUEURS TO DISTILLED MAHUA, INDIAN HERITAGE ALCOHOLIC BEVERAGES ARE HAVING THEIR DAY IN THE SUN
MISSING ADVISORS
INDIA HAS JUST ONE INVESTMENT ADVISOR FOR NEARLY EVERY 200,000 INVESTORS. AT A TIME WHEN RETAIL PARTICIPATION IN THE STOCK MARKETS IS BOOMING, THIS ASSUMES SIGNIFICANCE
TURNING A CORNER
SHARED ELECTRIC MOBILITY START-UP YULU'S SHIFT TO SERVICING THE QUICK COMMERCE SECTOR IS HELPING IT GROW FAST. IT IS NOW FOCUSSING ON IMPROVING ROAD SAFETY FEATURES AS IT TURNS EBITDA POSITIVE
REALITY CHECK
INDIAN STOCK MARKETS PLUNGED BEGINNING OCTOBER FOR A HOST OF REASONS, INCLUDING A FALL IN FII OWNERSHIP. HOW DEEP WILL THE CORRECTION BE?
TRUMP'S TRADE TANGO
The return of Donald Trump as the 47th President of the US has put the global economy on edge. India, too, is unlikely to remain unaffected. How will policymakers meet this latest challenge?
"The essence of the Trump administration will be transactional”
Global investor, analyst, and best-selling author Ruchir Sharma decodes why Donald Trump won the elections, what India should do, the risks, and more
